Login Register Cart 0
Generic placeholder image

Reviews on Recent Clinical Trials

Editor-in-Chief

ISSN (Print): 1574-8871
ISSN (Online): 1876-1038

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Perspective

Minimal Residual Disease in Multiple Myeloma: an Important Tool in Clinical Trials

Author(s): Alessandro Gozzetti* and Monica Bocchia

Volume 17, Issue 1, 2022

Published on: 13 January, 2022

Page: [9 - 10] Pages: 2

DOI: 10.2174/1574887116666211123092915

Abstract

Minimal residual disease (MRD) detection represents a great advancement in multiple myeloma. New drugs are now available that increase depth of response. The International Myeloma Working Group recommends using next-generation flow cytometry (NGF) or next-generation sequencing (NGS) to search for MRD in clinical trials. Best sensitivity thresholds have to be confirmed, as well as timing to detect it. MRD has proven as the best prognosticator in many trials and promises to enter also in clinical practice to guide future therapy.

Keywords: Multiple myeloma, minimal residual disease, next-generation flow, cure, complete remission, therapy.

« Previous Next »
Graphical Abstract

[1]
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin 2021; 71(1): 7-33.
[http://dx.doi.org/10.3322/caac.21654] [PMID: 33433946]
[2]
Gozzetti A, Candi V, Papini G, Bocchia M. Therapeutic advancements in multiple myeloma. Front Oncol 2014; 4: 241.
[http://dx.doi.org/10.3389/fonc.2014.00241] [PMID: 25237651]
[3]
Ocio EM, Richardson PG, Rajkumar SV, et al. New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). Leukemia 2014; 28(3): 525-42.
[http://dx.doi.org/10.1038/leu.2013.350] [PMID: 24253022]
[4]
Mohty M, Terpos E, Mateos MV, et al. Multiple myeloma treatment in real-world clinical practice: results of a prospective, multinational, noninterventional study. Clin Lymphoma Myeloma Leuk 2018; 18(10): e401-19.
[http://dx.doi.org/10.1016/j.clml.2018.06.018] [PMID: 30030033]
[5]
Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111(5): 2516-20.
[http://dx.doi.org/10.1182/blood-2007-10-116129] [PMID: 17975015]
[6]
Castillo JJ, Jurczyszyn A, Brozova L, et al. IgM myeloma: A multicenter retrospective study of 134 patients. Am J Hematol 2017; 92(8): 746-51.
[http://dx.doi.org/10.1002/ajh.24753] [PMID: 28383205]
[7]
Gozzetti A, Cerase A. Novel agents in CNS myeloma treatment. Cent Nerv Syst Agents Med Chem 2014; 14(1): 23-7.
[http://dx.doi.org/10.2174/1871524914999140818111514] [PMID: 25134940]
[8]
Kocoglu MH, Badros AZ. Newly diagnosed multiple myeloma: current treatment strategies, emerging therapeutic approaches and beyond. Expert Rev Hematol 2020; 13(6): 669-86.
[http://dx.doi.org/10.1080/17474086.2020.1756258] [PMID: 32290719]
[9]
Gozzetti A, Bacchiarri F, Sammartano V, et al. Long-term safety of rapid daratumumab infusions in multiple myeloma patients. Front Oncol 2020; 10: 570187.
[http://dx.doi.org/10.3389/fonc.2020.570187] [PMID: 33415072]
[10]
Flores-Montero J, Sanoja-Flores L, Paiva B, et al. Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia 2017; 31(10): 2094-103.
[http://dx.doi.org/10.1038/leu.2017.29] [PMID: 28104919]
[11]
Gozzetti A, Raspadori D, Bacchiarri F, et al. Minimal residual disease in multiple myeloma: state of the art and applications in clinical practice. J Pers Med 2020; 10(3): 120.
[http://dx.doi.org/10.3390/jpm10030120] [PMID: 32927719]
[12]
Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 2016; 17(8): e328-46.
[http://dx.doi.org/10.1016/S1470-2045(16)30206-6] [PMID: 27511158]
[13]
Munshi NC, Avet-Loiseau H, Anderson KC, et al. A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv 2020; 4(23): 5988-99.
[http://dx.doi.org/10.1182/bloodadvances.2020002827] [PMID: 33284948]
[14]
Facon T, Kumar S, Plesner T, et al. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med 2019; 380(22): 2104-15.
[http://dx.doi.org/10.1056/NEJMoa1817249] [PMID: 31141632]
[15]
Kaddoura M, Dingli D, Buadi FK, et al. Prognostic impact of posttransplant FDG PET/CT scan in multiple myeloma. Blood Adv 2021; 5(13): 2753-9.
[http://dx.doi.org/10.1182/bloodadvances.2020004131] [PMID: 34242392]
[16]
Lecouvet FE, Vekemans MC, Van Den Berghe T, et al. Imaging of treatment response and minimal residual disease in multiple myeloma: state of the art WB-MRI and PET/CT. Skeletal Radiol 2021.
[http://dx.doi.org/10.1007/s00256-021-03841-5] [PMID: 34363522]
[17]
Bertamini L, D’Agostino M, Gay F. MRD assessment in multiple myeloma: progress and challenges. Curr Hematol Malig Rep 2021; 16(2): 162-71.
[http://dx.doi.org/10.1007/s11899-021-00633-5] [PMID: 33950462]

Rights & Permissions Print Cite
Article Metrics
28
1
© 2024 Bentham Science Publishers | Privacy Policy